Milestone Pharmaceuticals Inc. (MIST) shareholders
MISTNasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.52−0.14 (-20.63%)
Close on Nov 13, 2026Market cap $64.74MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
40.8%
51M of 124M shares
Institutional holders
78
6 new, 13 sold out
Net institutional buying
11M
In Q2 2026
Insider trades, 12 months
0 buys · 13 sales
Net sold $1.18M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| RTW Investments, LP Joint filing with Roderick Wong (9.90%) | 12,356,953 | 9.90% | 13G (passive) amendment | Mar 31, 2026 |
| Roderick Wong Joint filing with RTW Investments, LP (9.90%) | 9,155,168 | 9.90% | 13G (passive) amendment | Sep 30, 2025 |
| Pavaki Capital Management LLC Joint filing with Pavaki Capital Partners, LP (7.30%), Ashok Rambhai Patel (7.30%) | 9,067,848 | 7.30% | 13G (passive) | Dec 31, 2025 |
| Trails Edge Biotechnology Master Fund, LP Joint filing with Trails Edge Capital Partners, LP (9.90%), Ortav Yehudai (9.90%) | 9,017,880 | 9.90% | 13G (passive) amendment | Sep 30, 2025 |
| Richard Kayne Joint filing with Propel Bio Management, LLC (9.90%), Leen Kawas (9.90%) and 1 more | 8,861,186 | 9.90% | 13G (passive) | Jul 11, 2025 |
| Robert Atchinson Joint filing with Adage Capital Management, L.P. (9.99%), Phillip Gross (9.99%) | 8,659,064 | 9.99% | 13G (passive) | Sep 30, 2025 |
| Phillip Gross Joint filing with Adage Capital Management, L.P. (6.37%), Robert Atchinson (6.37%) | 8,000,000 | 6.37% | 13G (passive) amendment | Mar 31, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of MIST | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Pavaki Capital Management LLC | 9,067,848 | 7.28% | $12.15M | +5,000 | 4.24% |
| Rtw Investments, LP | 7,833,336 | 6.29% | $10.50M | +1,502,335 | 0.09% |
| Propel Bio Management, LLC | 7,429,590 | 5.97% | $9.96M | +3,311,269 | 5.21% |
| Point72 Asset Management, L.P. | 5,411,138 | 4.35% | $7.25M | +4,325,455 | 0.01% |
| Simplify Asset Management Inc. | 3,349,379 | 2.69% | $4.49M | +1,842,974 | 0.06% |
| Millennium Management LLC | 3,142,219 | 2.52% | $4.21M | +1,597,894 | 0.00% |
| Kalehua Capital Management LLC | 2,538,474 | 2.04% | $3.40M | New | 1.09% |
| Two Sigma Investments, LP | 2,040,015 | 1.64% | $2.73M | −277,161 | 0.00% |
| Marshall Wace, Llp | 1,797,695 | 1.44% | $2.41M | −146,835 | 0.00% |
| Lion Point Capital, LP | 820,000 | 0.66% | $1.10M | – | 5.26% |
| Toronto Dominion Bank | 750,000 | 0.60% | $1.01M | – | 0.00% |
| Ameriprise Financial Inc | 666,666 | 0.54% | $893.33K | – | 0.00% |
| Boxer Capital Management, LLC | 666,666 | 0.54% | $893.33K | – | 0.07% |
| Morgan Stanley | 635,211 | 0.51% | $851.18K | −88,930 | 0.00% |
| UBS Group AG | 465,403 | 0.37% | $623.64K | −29,505 | 0.00% |
| Boothbay Fund Management, LLC | 462,669 | 0.37% | $619.98K | +293,994 | 0.01% |
| Susquehanna International Group, Llp | 359,895 | 0.29% | $482.26K | −159,151 | 0.00% |
| Aptus Capital Advisors, LLC | 339,450 | 0.27% | $454.86K | +59,200 | 0.00% |
| Guardian Wealth Advisors, LLC / Nc | 339,450 | 0.27% | $454.86K | +59,200 | 0.03% |
| Seven Fleet Capital Management LP | 270,233 | 0.22% | $362.11K | −63,100 | 0.06% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 78 | 51M | 40.8% | 6 / 23 | 23 / 13 | 16M | 5M |
| Q1 2026 | 87 | 40M | 31.7% | 21 / 23 | 19 / 14 | 12M | 8M |
| Q4 2025 | 80 | 35M | 28.1% | 29 / 21 | 9 / 9 | 16M | 15M |
| Q3 2025 | 61 | 34M | 27.4% | 26 / 18 | 4 / 7 | 25M | 3M |
| Q2 2025 | 43 | 12M | 9.5% | 10 / 10 | 9 / 10 | 1M | 1M |
| Q1 2025 | 43 | 12M | 9.5% | 14 / 6 | 11 / 17 | 3M | 16M |
| Q4 2024 | 47 | 25M | 19.7% | 10 / 14 | 14 / 6 | 2M | 6M |
| Q3 2024 | 43 | 29M | 23.0% | 5 / 9 | 10 / 1 | 5M | 4M |
| Q2 2024 | 40 | 32M | 25.6% | 3 / 9 | 7 / 6 | 3M | 4M |
| Q1 2024 | 43 | 33M | 26.5% | 11 / 13 | 7 / 7 | 16M | 1M |
| Q4 2023 | 40 | 19M | 14.9% | 8 / 9 | 10 / 7 | 3M | 4M |
| Q3 2023 | 39 | 20M | 15.7% | 2 / 9 | 14 / 11 | 0M | 2M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
5 funds held MIST in Q2 2026, 99% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of MIST | Value | % of fund | As of |
|---|---|---|---|---|---|
| Simplify Propel Opportunities ETF | 3,349,379 | 2.69% | $4.49M | 5.81% | Jun 30, 2026 |
| Invesco NASDAQ Future Gen 200 ETF | 44,936 | 0.04% | $63.81K | 0.34% | May 31, 2026 |
| Fidelity Nasdaq Composite Index Fund | 40,789 | 0.03% | $57.92K | 0.00% | May 31, 2026 |
| State Street(R) SPDR(R) S&P(R) International Small Cap ETF | 22,564 | 0.02% | $30.24K | 0.00% | Jun 30, 2026 |
| Blackstone Alternative Multi-Strategy Fund | 10,999 | 0.01% | $14.74K | 0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Joseph Oliveto | President and CEO, Director | 446,244 | 0.36% | Apr 20, 2026 |
| David I. Sandoval | GC & Chief Compliance Officer | – | – | Mar 23, 2026 |
| Amit Hasija | CFO & EVP of Corp. Development | 112,093 | 0.09% | Feb 5, 2026 |
| Lorenz Muller | Chief Commercial Officer | 205,406 | 0.16% | Feb 5, 2026 |
| David Bharucha | Chief Medical Officer | 125,426 | 0.10% | Feb 5, 2026 |
| Jeffrey Edward Nelson | Chief Operating Officer | 49,848 | 0.04% | Feb 5, 2026 |
| Stuart Duty | Director | – | – | Jun 12, 2026 |
| Robert James Wills | Director | 65,000 | 0.05% | Jun 12, 2026 |
| Joseph C. Papa | Director | 100,000 | 0.08% | Jun 12, 2026 |
| Seth H. Z. Fischer | Director | – | – | Jun 12, 2026 |
| Michael John Tomsicek | Director | 15,000 | 0.01% | Jun 12, 2026 |
| Andrew Saik | Director | – | – | Jun 12, 2026 |
| Lisa M. Giles | Director | – | – | Jun 12, 2026 |
| Debra K. Liebert | Director | 30,793 | 0.02% | Jul 15, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Joseph Oliveto President and CEO, Director | Apr 16, 2026 | Sale(10b5-1 plan) | −36,500 | $2.26 | $82.49K | 446,244 |
| Joseph Oliveto President and CEO, Director | Jan 26, 2026 | Option exercise | +66,600 | – | – | 517,267 |
| Joseph Oliveto President and CEO, Director | Jan 26, 2026 | Sale | −34,523 | $1.93 | $66.63K | 482,744 |
| Jeffrey Edward Nelson Chief Operating Officer | Jan 26, 2026 | Sale | −12,245 | $1.93 | $23.63K | 49,848 |
| Jeffrey Edward Nelson Chief Operating Officer | Jan 26, 2026 | Option exercise | +20,100 | – | – | 62,093 |
| Amit Hasija CFO & EVP of Corp. Development | Jan 26, 2026 | Option exercise | +20,100 | – | – | 112,093 |
| Amit Hasija CFO & EVP of Corp. Development | Jan 26, 2026 | Sale | −12,245 | $1.93 | $23.63K | 99,848 |
| Lorenz Muller Chief Commercial Officer | Jan 26, 2026 | Sale | −11,180 | $1.93 | $21.58K | 205,406 |
| Lorenz Muller Chief Commercial Officer | Jan 26, 2026 | Option exercise | +20,100 | – | – | 216,586 |
| David Bharucha Chief Medical Officer | Jan 26, 2026 | Option exercise | +20,100 | – | – | 125,426 |
| David Bharucha Chief Medical Officer | Jan 26, 2026 | Sale | −12,245 | $1.93 | $23.63K | 113,181 |
| Joseph Oliveto President and CEO, Director | Jan 8, 2026 | Sale(10b5-1 plan) | −43,000 | $2.25 | $96.75K | 303,721 |
| Joseph Oliveto President and CEO, Director | Jan 7, 2026 | Sale(10b5-1 plan) | −500 | $2.25 | $1.13K | 346,721 |
| Joseph Oliveto President and CEO, Director | Dec 15, 2025 | Sale | −133,054 | $2.32 | $308.69K | 450,667 |
| Jeffrey Edward Nelson Chief Operating Officer | Dec 15, 2025 | Sale | −58,007 | $2.32 | $134.58K | 41,993 |
| Amit Hasija CFO & EVP of Corp. Development | Dec 15, 2025 | Sale | −58,007 | $2.32 | $134.58K | 91,993 |
| Lorenz Muller Chief Commercial Officer | Dec 15, 2025 | Sale | −53,566 | $2.32 | $124.27K | 196,486 |
| David Bharucha Chief Medical Officer | Dec 15, 2025 | Sale | −58,007 | $2.32 | $134.58K | 105,326 |
| Joseph Oliveto President and CEO, Director | Dec 12, 2025 | Award | +280,000 | – | – | 583,721 |
| Jeffrey Edward Nelson Chief Operating Officer | Dec 12, 2025 | Award | +100,000 | – | – | 100,000 |
| Amit Hasija CFO & EVP of Corp. Development | Dec 12, 2025 | Award | +100,000 | – | – | 150,000 |
| Lorenz Muller Chief Commercial Officer | Dec 12, 2025 | Award | +100,000 | – | – | 250,052 |
| David Bharucha Chief Medical Officer | Dec 12, 2025 | Award | +100,000 | – | – | 163,333 |
| Lorenz Muller Chief Commercial Officer | Dec 9, 2025 | Gift | −25,000 | – | – | 150,052 |
| Debra K. Liebert Director | Jul 11, 2025 | Award | +16,666 | – | – | 16,793 |
| Joseph C. Papa Director | Jul 11, 2025 | Award | +100,000 | – | – | 100,000 |
| Amit Hasija CFO & EVP of Corp. Development | Jul 11, 2025 | Award | +50,000 | – | – | 50,000 |
| Lorenz Muller Chief Commercial Officer | Jul 11, 2025 | Award | +66,666 | – | – | 175,052 |
| David Bharucha Chief Medical Officer | Jul 11, 2025 | Award | +53,333 | – | – | 63,333 |
| Robert James Wills Director | Jul 11, 2025 | Award | +50,000 | – | – | 65,000 |
| Joseph Oliveto President and CEO, Director | Jul 11, 2025 | Award | +66,666 | – | – | 347,221 |
| Roderick Wong 10% owner | Mar 22, 2023 | Other | −1,059,000 | – | – | 3,256,102 |
| David Bharucha Chief Medical Officer | Dec 5, 2022 | Buy | +7,000 | $4.69 | $32.83K | 10,000 |
| David Bharucha Chief Medical Officer | Dec 1, 2022 | Buy | +3,000 | $4.86 | $14.58K | 3,000 |
| Debra K. Liebert Director | Oct 21, 2022 | Buy | +4,000 | $5.26 | $21.04K | 4,000 |
| Richard C. Pasternak Director | Oct 20, 2022 | Buy | +10,000 | $5.20 | $52.00K | 10,000 |
| Debra K. Liebert Director | Oct 20, 2022 | Buy | +10,000 | $5.29 | $52.90K | 10,000 |
| Robert James Wills Director | Oct 19, 2022 | Buy | +15,000 | $4.93 | $73.95K | 15,000 |
| Michael John Tomsicek Director | Oct 19, 2022 | Buy | +15,000 | $5.32 | $79.80K | 15,000 |
| Debra K. Liebert Director | Sep 14, 2022 | Other | +127 | – | – | 127 |
| Rtw Investments, Lp 10% owner | Sep 7, 2022 | Sale | −1,557,346 | $8.71 | $13.56M | 4,315,102 |
| Rtw Investments, Lp 10% owner | Sep 7, 2022 | Buy | +1,557,346 | $8.71 | $13.56M | 4,315,102 |
| Paul F. Truex Director | May 31, 2022 | Option exercise | +8,016 | $1.12 | $8.98K | 8,016 |
| Paul F. Truex Director | May 31, 2022 | Option exercise | +45,072 | $1.54 | $69.41K | 53,088 |
| Paul F. Truex Director | May 31, 2022 | Option exercise | +22,870 | $1.54 | $35.22K | 75,958 |
| Paul F. Truex Director | May 31, 2022 | Option exercise | +822 | $2.66 | $2.19K | 76,780 |
| Paul F. Truex Director | May 31, 2022 | Buy | +5,000 | $5.60 | $28.00K | 81,780 |
| Lorenz Muller Chief Commercial Officer | Aug 26, 2020 | Option exercise | +5,700 | $1.54 | $8.78K | 108,386 |
| De Solidarite Des Travailleurs Du Quebec Fonds 10% owner | Jul 29, 2020 | Sale | −500,000 | $8.32 | $4.16M | 2,254,920 |
| De Solidarite Des Travailleurs Du Quebec Fonds 10% owner | Jul 28, 2020 | Sale | −19,863 | $8.10 | $160.89K | 2,754,920 |
| Lorenz Muller Chief Commercial Officer | Apr 3, 2020 | Option exercise | +32,528 | $1.54 | $50.09K | 84,643 |
| Lorenz Muller Chief Commercial Officer | Apr 3, 2020 | Option exercise | +18,043 | $1.54 | $27.79K | 102,686 |
| Rtw Investments, Lp 10% owner | Mar 19, 2020 | Buy | +5,870 | $10.87 | $63.81K | 4,315,102 |
| Rtw Investments, Lp 10% owner | Mar 18, 2020 | Buy | +2,705 | $10.36 | $28.02K | 4,309,232 |
| Rtw Investments, Lp 10% owner | Mar 2, 2020 | Buy | +78,263 | $18.95 | $1.48M | 4,306,527 |
| Roderick Wong 10% owner | Jan 13, 2020 | Buy | +270,000 | $16.25 | $4.39M | 4,228,264 |
| Rtw Investments, Lp 10% owner | Dec 31, 2019 | Buy | +21,438 | $15.50 | $332.29K | 3,958,264 |
| Rtw Investments, Lp 10% owner | Dec 30, 2019 | Buy | +1,333 | $15.48 | $20.63K | 3,936,826 |
| Joseph Oliveto President and CEO, Director | Dec 21, 2019 | Option exercise | +7,400 | $1.54 | $11.40K | 280,555 |
| Holdings A/S Novo 10% owner | Nov 25, 2019 | Sale | −240,000 | $16.00 | $3.84M | 2,434,470 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Short % of float
16.13%
20M shares short
Days to cover
24.8
At 1M shares a day
Change since last report
+0.9%
From 20M shares
Short volume, 20 days
35.4%
Of volume reported to FINRA
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Milestone Pharmaceuticals's stock actually held short. Settlement fails (shares not delivered on time) peaked at 145,582 shares on Aug 21, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Joseph Oliveto Director, Officer | Apr 16, 2026 | 36,500 | $80.30K | Apr 16, 2026 | Previously Exercised Stock Options |
| Joseph Oliveto Director, Officer | Jan 8, 2026 | 79,500 | $170.93K | Jan 8, 2026 | Previously Exercised Stock Options |
| Joseph Oliveto Officer | Jan 7, 2026 | 500 | $1.03K | Jan 7, 2026 | Previously Exercised Stock Options |
See a number that looks wrong?